Patrick Neven, MD, Universitair Ziekenhuis Leuven, Leuven, Belgium, shares key updates in selective estrogen receptor degrader or downregulators (SERDs) from the San Antonio Breast Cancer Symposium (SABCS) 2022, including from the Phase III EMERALD (NCT03778931) trial and the Phase II SERENA-2 (NCT04214288) trial. The EMERALD trial compared elacestrant to the standard of care, fulvestrant, in patients with ER+/HER2-metastaic breast cancer. The primary results had shown elacestrant to be superior to fulvestrant. Updated results presented at SABCS 2022 based on duration of prior treatment with CDK4/6 inhibitors (CDK4/6i) demonstrated duration of prior CDK4/6i was positively associated with progression-free survival (PFS). The SERENA-2 trial compared camizestrant versus fulvestrant in women with advanced ER+/HER2- breast cancer demonstrated an improved PFS with camizestrant. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) 2022 in San Antonio, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
